SCHEMBL8286229

SCHEMBL8286229

NC(=O)C1(NCC2CCCCC2)CCN(C2CCCCC2=O)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 1/20 0.37
OPRM1 P35372 2/20 0.35
OPRD1 P41143 2/20 0.35
OPRK1 P41145 2/20 0.35
POLB P06746 1/20 0.35
HTT P42858 2/20 0.35
ALDH1A1 P00352 1/20 0.35
OPRL1 P41146 2/20 0.32
HDAC6 Q9UBN7 1/20 0.32
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
PPIA P62937 2/20 0.31
CYP2D6 P10635 1/20 0.31
HRH3 Q9Y5N1 1/20 0.30
MEN1 O00255 1/20 0.30
APEX1 P27695 1/20 0.30
KMT2A Q03164 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
PARP1 P09874 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8286224 0.83 SLC18A3 (0.37) SLC18A3POLBHTTALDH1A1OPRL1
SCHEMBL8285370 0.82 SLC18A3 (0.36) SLC18A3OPRM1OPRK1POLBHTT
SCHEMBL8286582 0.81 SLC18A3 (0.36) SLC18A3POLBHTTALDH1A1OPRL1
SCHEMBL8285372 0.75 SLC18A3 (0.50) SLC18A3OPRM1OPRD1OPRK1HTT
SCHEMBL8287289 0.74 SLC18A3 (0.40) SLC18A3HTTALDH1A1MAPTHPGD
SCHEMBL8892930 0.71 ALDH1A1 (0.62) OPRM1OPRD1OPRK1ALDH1A1OPRL1
SCHEMBL12563615 0.70 TDP1 (0.40) ALDH1A1OPRL1MAPTCYP2D6KMT2A
SCHEMBL23595723 0.68 SLC18A3 (0.57) SLC18A3POLBALDH1A1MAPTKMT2A
SCHEMBL10562193 0.68 SLC18A3 (0.57) SLC18A3POLBALDH1A1MAPTKMT2A
SCHEMBL491782 0.68 SLC18A3 (0.57) SLC18A3POLBALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005040166-A1 TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS F.HOFFMANN-LA ROCHE AG (CH) 2005-05-06 WO disclosed